BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Paclitaxel: trial readouts and FDA decisions
22 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 21 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Akeso, Merck Sharp & Dohme LLC, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd., AstraZeneca, Tesaro, Inc., Sichuan Baili Pharmaceutical Co., Ltd., Mabscale, LLC, Tesaro, Inc., Sichuan Baili Pharmaceutical Co., Ltd., Mabscale, LLC, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., RemeGen Co., Ltd., Eikon Therapeutics, Suzhou Suncadia Biopharmaceuticals Co., Ltd., GlaxoSmithKline, Nanjing Leads Biolabs Co.,Ltd, CanariaBio Inc., NATCO Pharma Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, AskGene Pharma, Inc., Shanghai Jiaolian Drug Research and Development Co., Ltd, CStone Pharmaceuticals, Gilead Sciences, Jiangsu HengRui Medicine Co., Ltd., Bristol-Myers Squibb, Innovent Biologics (Suzhou) Co. Ltd., Shanghai Runshi Pharmaceutical Technology Co., Ltd, Qilu Pharmaceutical Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd., Arcus Biosciences, Inc., Bio-Thera Solutions, Daiichi Sankyo, Regeneron Pharmaceuticals, Genmab, DualityBio Inc., Actuate Therapeutics Inc.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-20 est. | P3 | Merck Sharp & Dohme LLC MRK | NCT04634877 Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer | Endometrial Neoplasms | active not recruiting | 990 |
| 2026-11-26 est. | P3 | Tesaro, Inc. | NCT03981796 A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endome | Neoplasms | active not recruiting | 785 |
| 2026-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05054439 A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC | Head and Neck Squamous Cell Carcinoma | active not recruiting | 45 |
| 2026-12 est. | P3 | Mabscale, LLC | NCT05654454 A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer | recruiting | 620 |
| 2026-12 est. | P1/P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06202261 A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer | Metastatic Breast Cancer; Recurrent Breast Cancer; Advanced Malignancies | recruiting | 154 |
| 2026-12 est. | P2/P3 | RemeGen Co., Ltd. | NCT06221748 DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therap | Gastric Cancer; Gastroesophageal Junction Adenocarcinoma | recruiting | 90 |
| 2026-12 est. | P2 | Eikon Therapeutics EIKN | NCT06246110 A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC | NSCLC | active not recruiting | 70 |
| 2026-12 est. | P1/P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06840002 A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer | Ovarian Cancer | recruiting | 150 |
| 2026-12 est. | P1/P2 | Akeso | NCT06943820 AK129 Combination Therapy for Advanced Solid Tumors | Non-small Cell Lung Cancer Stage IIIB/IV; Head and Neck Squamous Cell Carcinoma (HNSCC); Colorectal | recruiting | 230 |
| 2026-12-14 est. | P2 | GlaxoSmithKline | NCT06317311 A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer | Carcinoma | active not recruiting | 41 |
| 2026-12-24 est. | P2 | Nanjing Leads Biolabs Co.,Ltd | NCT06783647 A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)] | Advanced Solid Tumour | recruiting | 250 |
| 2026-12-26 est. | P3 | CanariaBio Inc. | NCT04498117 Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | Carcinoma, Ovarian Epithelial; Ovarian Neoplasms; Ovarian Cancer; Ovarian Serous Adenocarcinoma; Fal | active not recruiting | 615 |
| 2026-12-30 est. | P2 | Akeso | NCT05227664 A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer | Metastatic Triple-negative Breast Cancer; Locally Advanced Triple-negative Breast Cancer | active not recruiting | 120 |
| 2026-12-30 est. | P2 | NATCO Pharma Ltd. | NCT05283226 Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous | Carcinoma; Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma | recruiting | 21 |
| 2026-12-30 est. | P3 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | NCT06751485 JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer | Ovarian Cancer; Primary Peritoneal; Fallopian Tube Cancers | not yet recruiting | 430 |
| 2026-12-31 est. | P1/P2 | AskGene Pharma, Inc. | NCT05867420 A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. | Advanced Solid Tumors | recruiting | 594 |
| 2026-12-31 est. | P2 | Shanghai Jiaolian Drug Research and Development Co., Ltd | NCT06434610 A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer. | Platinum-resistant Recurrent Ovarian Cancer | recruiting | 90 |
| 2027-01 est. | P1/P2 | CStone Pharmaceuticals | NCT06741644 A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors | Advanced Solid Tumors | recruiting | 800 |
| 2027-02 est. | P3 | Gilead Sciences GILD | NCT05382286 Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Ad | Triple Negative Breast Cancer; PD-L1 Positive | active not recruiting | 443 |
| 2027-02 est. | P1/P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT07136142 A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors | Malignant Solid Tumor | recruiting | 150 |
| 2027-02-05 est. | P2 | Bristol-Myers Squibb BMY | NCT06946797 A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Un | Non-Small Cell Lung Cancer | active not recruiting | 76 |
| 2026-12-30 est. | P3 | Innovent Biologics (Suzhou) Co. Ltd. | NCT06238843 A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, | Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | active not recruiting | 464 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-13 est. | P1/P2 | Shanghai Runshi Pharmaceutical Technology Co., Ltd | NCT06682611 Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors. | Unresectable Locally Advanced or Metastatic Solid Tumors | not yet recruiting | 380 |
| 2026-11 est. | P3 | Akeso | NCT06341335 A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma | Gastric and Gastroesophageal Junction Adenocarcinoma | recruiting | 506 |
| 2026-10-19 | P3 | Merck Sharp & Dohme LLC MRK | NCT06356311 A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) | Gastroesophageal Cancer | active not recruiting | 473 |
| 2026-10 est. | P1/P2 | Qilu Pharmaceutical Co., Ltd. | NCT07256782 A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors | Advanced Solid Tumor | recruiting | 444 |
| 2026-10 est. | P2 | Shanghai Hengrui Pharmaceutical Co., Ltd. | NCT07229729 A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer | Non-small Cell Lung Cancer | recruiting | 300 |
| 2026-09-30 est. | P3 | Innovent Biologics (Suzhou) Co. Ltd. | NCT05116462 Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer | Non-Small Cell Lung Cancer | active not recruiting | 506 |
| 2026-09-17 | P2 | Arcus Biosciences, Inc. RCUS | NCT04736173 Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer | Non Small Cell Lung Cancer; Nonsquamous Non Small Cell Lung Cancer; Squamous Non Small Cell Lung Can | completed | 169 |
| 2026-09 est. | P2/P3 | Bio-Thera Solutions | NCT06123884 BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer | Cervical Cancer | recruiting | 526 |
| 2026-08-31 est. | P3 | Daiichi Sankyo | NCT04704934 Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-C | Gastric Cancer, Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma | active not recruiting | 490 |
| 2026-08-24 est. | P2 | Regeneron Pharmaceuticals REGN | NCT06161441 A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in A | Resectable Non-small Cell Lung Cancer | active not recruiting | 195 |
| 2026-08-18 | P3 | Genmab GMAB | NCT06619236 Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer | Platinum-resistant Ovarian Cancer | active not recruiting | 584 |
| 2026-08-17 | P3 | AstraZeneca AZN | NCT05984277 A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. | Metastatic Non-small Cell Lung Cancer | active not recruiting | 895 |
| 2026-08-12 | P3 | DualityBio Inc. | NCT06018337 A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) | Metastatic Breast Cancer | active not recruiting | 541 |
| 2026-07 est. | P3 | Shanghai Hengrui Pharmaceutical Co., Ltd. | NCT06738251 A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | recruiting | 402 |
| 2026-07 est. | P2 | Akeso | NCT04736823 A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC | NSCLC | active not recruiting | 265 |
| 2026-06-30 est. | P1/P2 | Akeso | NCT05904379 AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer | Advanced Non-small-cell Lung Cancer | active not recruiting | 233 |
| 2026-06-15 | P3 | Merck Sharp & Dohme LLC MRK | NCT05298423 Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemora | Carcinoma, Non-Small-Cell Lung | completed | 610 |
| 2026-06 est. | P2 | Actuate Therapeutics Inc. ACTU | NCT03678883 9-ING-41 in Patients With Advanced Cancers | Cancer; Pancreatic Cancer; Sarcoma; Renal Cancer; Refractory Cancer; Refractory Neoplasm; Refractory | active not recruiting | 350 |
| 2026-05-31 est. | P3 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06394492 SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer | Ovarian Cancer | recruiting | 440 |
| 2026-05-31 | P3 | AstraZeneca AZN | NCT06346392 AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Ad | Gastric Cancer; Gastroesophageal Junction Cancer | active not recruiting | 594 |
| 2026-05-31 | P2 | Akeso | NCT05932212 AK104 for Recurrent or Metastatic Vulvar Cancer | Vulvar Cancer | terminated | 20 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.